uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Show others and affiliations
2010 (English)In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 95, no 3, 292-297 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND AND PURPOSE: In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer. MATERIAL AND METHODS: Thirty-nine patients with inextirpable adenocarcinoma of the pancreas, gallbladder or extrahepatic bile ducts were included. Two cycles of XELOX (capecitabine 1000mg/m(2) bid d1-14+oxaliplatin 130mg/m(2) d1, q3w) were followed by XELOX-RT (radiotherapy (50.4Gy), combined with capecitabine 750-675mg/m(2) bid every radiotherapy day and oxaliplatin 40-30mg/m(2) once weekly). Primary end-points were tolerance (phase I) and objective response (phase II). RESULTS: The maximum tolerated doses of oxaliplatin and capecitabine to combine with irradiation were 30mg/m(2) and 675mg/m(2), respectively. Twenty-one percent (95% CI: 9-38%) of evaluable patients achieved partial response. Five patients went through surgery (three R0 resections). Two-year survival was 28%, and estimated local tumour control rate at 2 years was 72%. The most common grade 3-4 toxicity was nausea and vomiting. CONCLUSIONS: XELOX-RT (30mg/m(2) oxaliplatin/675mg/m(2) capecitabine in combination with 50.4Gy/28 fractions) was well tolerated and effective for locally advanced pancreatic and biliary tract cancer.

Place, publisher, year, edition, pages
2010. Vol. 95, no 3, 292-297 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-125793DOI: 10.1016/j.radonc.2010.04.004ISI: 000279038400006PubMedID: 20451275OAI: oai:DiVA.org:uu-125793DiVA: diva2:321043
Available from: 2010-05-28 Created: 2010-05-28 Last updated: 2017-12-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Oncology
In the same journal
Radiotherapy and Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 349 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf